Preventing Obstructions of Nanosized Drug Delivery Systems by the Extracellular Matrix

Abstract

Although nanosized drug delivery systems are promising tools for the treatment of severe diseases, the extracellular matrix (ECM) constitutes a major obstacle that endangers therapeutic success. Mobility of diffusing species is restricted not only by small pore size (down to as low as 3 nm) but also by electrostatic interactions with the network. This article evaluates commonly used in vitro models of ECM, analytical methods, and particle types with respect to their similarity to native conditions in the target tissue. In this cross-study evaluation, results from a wide variety of mobility studies are analyzed to discern general principles of particle–ECM interactions. For instance, cross-linked networks and a negative network charge are essential to reliably recapitulate key features of the native ECM. Commonly used ECM mimics comprised of one or two components can lead to mobility calculations which have low fidelity to in vivo results. In addition, analytical methods must be tailored to the properties of both the matrix and the diffusing species to deliver accurate results. Finally, nanoparticles must be sufficiently small to penetrate the matrix pores (ideally R_d/p < 0.5; d = particle diameter, p = pore size) and carry a neutral surface charge to avoid obstructions. Larger (R_d/p >> 1) or positively charged particles are trapped.

Nanoparticle obstruction by the extracellular matrix endangers therapeutic success. Mobility is restricted by the small pores of the matrix and by electrostatic interactions with the network. Only particle diameters that do not exceed the pore sizes of the matrix (R_d/p < 1) and that have neutral or negative surface charge can pass the barrier. Larger or positively charged particles are trapped.

http://ift.tt/2zpFPFp